ERBB2 and cancer: Regarding the other mutations found in our series, the p.I767M mutation was also not functionally characterized as oncogenic, but appeared sensitive to conventional anti-ERBB2 drugs (trastuzumab, lapatinib, neratinib) [14]; the p.S310Y mutation has been functionally characterized as activating mutations that sensitize cancer cells to ERBB2 inhibitors [13].